Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.47 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13384650 | 1.00 | HTR2C (0.58) | HTR2CSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL19598727 | 1.00 | HTR2C (0.58) | HTR2CSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL13489645 | 1.00 | HTR2C (0.58) | HTR2CSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL3720336 | 0.92 | HTR2C (0.54) | HTR2CSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL31537934 | 0.87 | TSHR (0.52) | HTR2CSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL15218647 | 0.86 | SMN1; SMN2 (0.60) | HTR2CSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL14372548 | 0.86 | SMN1; SMN2 (0.60) | HTR2CSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL16472423 | 0.86 | SMN1; SMN2 (0.60) | HTR2CSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL13156576 | 0.85 | SMN1; SMN2 (0.58) | HTR2CSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL18912571 | 0.85 | SMN1; SMN2 (0.60) | HTR2CSMN1; SMN2NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242742-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-8343966-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-01-01 | — | — | US | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
| US-7569690-B2 | Process for producing oxycarbonyl-substituted piperazine derivative | TORAY FINE CHEMICALS CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20060161003-A1 | Process for producing oxycarbonyl-substituted piperazine derivative | TORAY FINE CHEMICALS CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1548010-A1 | PROCESS FOR PRODUCING OXYCARBONYL-SUBSTITUTED PIPERAZINE DERIVATIVE | Toray Fine Chemicals Co., Ltd. (JP) | 2005-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | HTR2C 4583/4885SMN1; SMN2 612/4885NPC1 1909/4885 |
| US-20060161003-A1 | Process for producing oxycarbonyl-substituted piperazine derivative | DHPS, AQP4, OGFOD1 | HTR2C 1230/4885SMN1; SMN2 3473/4885NPC1 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.